Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research programme focused on autoimmune diseases
Posted: 24 March 2015 | Victoria White
Bristol-Myers Squibb acquires license from Novo Nordisk for a discovery biologics research programme focused on modulating the innate immune system…
Bristol-Myers Squibb Company (NYSE:BMY) today announced the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research programme focused on modulating the innate immune system as a therapy for autoimmune diseases. Terms of the agreement were not disclosed.
Agreement supports Bristol-Myers Squibb’s commitment to immunoscience
The agreement supports Bristol-Myers Squibb’s long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.
The innate immune system is the body’s first line of defense against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
For more information on Bristol-Myers Squibb, please visit www.bms.com.
Related topics
Drug Discovery
Related organisations
Bristol-Myers Squibb, Novo Nordisk
